Stephen J Pettitt

List of Publications by Year
in descending order

38	3,100	304368	315357
papers	citations	22 h-index	38 g-index

41	41	41	5321
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The shieldin complex mediates 53BP1-dependent DNA repair. Nature, 2018, 560, 117-121.	13.7	445
2	Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nature Methods, 2009, 6, 493-495.	9.0	340
3	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nature Communications, 2018, 9, 1849.	5.8	310
4	PARP inhibition enhances tumor cellâ€“intrinsic immunity in ERCC1-deficient nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	3.9	222
5	Structural basis for allosteric PARP-1 retention on DNA breaks. Science, 2020, 368, .	6.0	191
6	Polζ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nature Communications, 2021, 12, 3636.	5.8	159
7	A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity. PLoS ONE, 2013, 8, e61520.	1.1	147
8	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. Cell Reports, 2018, 23, 2107-2118.	2.9	110
9	Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer Discovery, 2020, 10, 1475-1488.	7.7	109
10	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British Journal of Cancer, 2017, 117, 113-123.	2.9	84
11	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Nonâ€“BRCA1/2-Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	7.7	82
12	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Cancer Discovery, 2018, 8, 498-515.	7.7	79
13	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	2.9	78
14	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827.	7.7	78
15	The piggyBac Transposon Displays Local and Distant Reintegration Preferences and Can Cause Mutations at Noncanonical Integration Sites. Molecular and Cellular Biology, 2013, 33, 1317-1330.	1.1	77
16	Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. Molecular Cell, 2021, 81, 767-783.e11.	4.5	72
17	Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Molecular Cancer Therapeutics, 2017, 16, 2022-2034.	1.9	66
18	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902.	0.4	66

#	Article	IF	Citations
19	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nature Cell Biology, 2022, 24, 62-73.	4.6	66
20	ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Research, 2017, 77, 7014-7026.	0.4	43
21	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. European Urology, 2021, 80, 243-253.	0.9	28
22	Resistance to <scp>DNA</scp> repair inhibitors in cancer. Molecular Oncology, 2022, 16, 3811-3827.	2.1	28
23	Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene, 2018, 37, 5701-5718.	2.6	24
24	Genome-Wide Forward Genetic Screens in Mouse ES Cells. Methods in Enzymology, 2010, 477, 217-242.	0.4	22
25	Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nature Communications, 2018, 9, 2016.	5.8	22
26	Dissecting PARP inhibitor resistance with functional genomics. Current Opinion in Genetics and Development, 2019, 54, 55-63.	1.5	22
27	Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery. Molecular Cell, 2022, 82, 2939-2951.e5.	4.5	22
28	Isolation of homozygous mutant mouse embryonic stem cells using a dual selection system. Nucleic Acids Research, 2012, 40, e21-e21.	6.5	21
29	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut, 2018, 67, 1780-1792.	6.1	19
30	Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. Scientific Data, 2017, 4, 170020.	2.4	14
31	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports, 2018, 8, 10614.	1.6	13
32	piggyBac Transposon-Based Insertional Mutagenesis in Mouse Haploid Embryonic Stem Cells. Methods in Molecular Biology, 2015, 1239, 15-28.	0.4	11
33	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
34	Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. Oncogene, 2022, 41, 3969-3977.	2.6	6
35	Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. Journal of Pathology: Clinical Research, 2020, 6, 3-11.	1.3	5
36	PARP inhibitors and breast cancer: highlights and hang-ups. Expert Review of Precision Medicine and Drug Development, 2018, 3, 83-94.	0.4	4

#	Article	IF	Citations
37	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8.	3.2	4
38	Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. Communications Biology, 2021, 4, 1270.	2.0	4